Abstract
https://www.nejm.org/doi/full/10.1056/NEJMoa2309169
1 clinical trial
1 product
1 drug
1 indication
Clinical trial
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha ExpressionStatus: Active (not recruiting), Estimated PCD: 2023-09-01
Indication
Ovarian CancerProduct
Mirvetuximab Soravtansine